Clinical trial · Interventional
Sentinel Lymph Node Mapping With Different Injection Sites of ICG in Endometrium Cancer
A Prospective, Randomized Trial Comparing the Different Injection Sites of Indocyanine Green (ICG) in Sentinel Lymph Node Mapping in Patients With Endometrial Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary goal of this prospective study is to define the efficacy of the sentinel lymph node biopsy (SLNB) procedure by comparing different method performed in patients with endometrial cancer. The aim of this study is to investigate whether the detection rate of sentinel lymph node (SLN) with two different injection sites may be increased compared to the standard use with single site (cervix) injection in endometrial cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| injecting indocyanine green (ICG) dye Intraoperative | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- sentinel lymph node mapping with One injection site (cervix) group
- description
- injecting indocyanine green (ICG) dye Intraoperative in cervix
- interventionNames
- Procedure: injecting indocyanine green (ICG) dye Intraoperative
- type
- EXPERIMENTAL
- label
- sentinel lymph node mapping with two injection site (cervix-uterus) group
- description
- injecting indocyanine green (ICG) dye Intraoperative in cervix and uterus
- interventionNames
- Procedure: injecting indocyanine green (ICG) dye Intraoperative
Primary outcomes (2)
- measure
- paraaortic Sentinel lymph node detection rates
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * • 1.Age \>18 and \<80 years old * 2\. The pathological diagnosis was epithelial ovarian cancer * 3.Survival time is expected to exceed 3 months * 4.Signed consent form Exclusion Criteria: * 1\. Patients with myocardial infarction or stroke, or unstable angina pectoris or decompensated heart function * 2.Patients with a history of exhaustion or deep vein thrombosis; * 3\. Liver insufficiency (transaminase \>2.5 times the upper limit of the standard); * 4\. Renal insufficiency (serum muscle liver \>2 times the standard upper limit); * 5\. Pregnancy and perinatal patients; * 6\. History of major organ transplantation and immune disease; * 7\. Psychiatric condition or language barriers * 8\. Alcohol or drug abuser (current or previous) * 9\. Unable or unwilling to sign informed consent or comply with study requirements; * 10\. Patients with other malignant tumors.
References
Publications (0)
Data not yet available